Glomerular glucocorticoid receptor expression is reduced in late responders to steroids in adult-onset minimal change disease by 문성진 et al.
Original Article
Glomerular glucocorticoid receptor expression is reduced in late
responders to steroids in adult-onset minimal change disease
Seung Hyeok Han1,*, Sun Young Park1,*, Jin-Ji Li2, Seung Jae Kwak1, Dong Sub Jung1,
Hoon Young Choi1, Jung Eun Lee1, Sung Jin Moon1, Dong Ki Kim1, Dae-Suk Han1 and
Shin-Wook Kang1
1Department of Internal Medicine, College of Medicine, Brain Korea 21, Yonsei University, Seoul, Korea, and
2Nephrology and Dialysis Unit, Department of Internal Medicine, The Affiliated Hospital, YanBian University
Medical College, JiLin, China
Abstract
Background. Compared to children, adult patients with
minimal change disease (MCD) tend to have a slower
response to steroids, but little is known about the
factors influencing the steroid responsiveness in these
patients. In this study, we investigated the difference in
the expression of the glomerular glucocorticoid recep-
tor (GCR) according to steroid responsiveness in 28
adult-onset MCD patients.
Methods. Based on the response to steroid treatment,
the patients were divided into early responders (ER,
n¼ 20) and late responders (LR, n ¼ 8) according to
the response to steroids on the basis of 4 weeks of
treatment. The clinical and laboratory findings, and
the glomerular mRNA and protein expression of GCR
and nephrin, assessed by real-time polymerase chain
reaction and immunohistochemistry, respectively, were
compared between the ER and LR groups. Ten
microscopic haematuric patients in whom renal
biopsy was performed and revealed no histological
abnormalities were included for control (C).
Results. The mRNA expression of GCR was signifi-
cantly lower in the LR than that in the ER group
(P< 0.01), whereas it was comparable between the C
and ER groups. GCR protein expression was also
decreased in the LR compared with the C and ER
groups. In contrast, there was no significant difference
in nephrin mRNA expression among the three groups.
On the other hand, the GCR mRNA expression
correlated inversely with the time to complete remis-
sion (r¼0.49, P< 0.05), but not with the amount of
proteinuria at presentation.
Conclusion. In conclusion, the levels of glomerular
GCR expression may be a useful predictor of steroid
responsiveness in adult-onset MCD patients.
Keywords: glucocorticoid receptor; minimal change
disease; real-time PCR; steroid responsiveness
Introduction
Minimal change disease (MCD) is the most common
pathological finding of nephrotic syndrome in
children, accounting for more than 75% of cases,
whereas only 20–30% of adult patients with nephrotic
syndrome have MCD [1]. In general, three-fourths of
the children with MCD achieve remission within
2 weeks, and roughly 95% within 8 weeks from starting
steroid treatment [2,3]. On the other hand, adult-onset
MCD patients have a tendency to respond to steroids
slowly, requiring longer duration of high-dose gluco-
corticoid treatment than children with MCD [4,5].
Glucocorticoid is the drug of choice for patients with
MCD, but in whom its action mechanism is still
unclear. Glucocorticoid exerts its action by binding to
the intracellular glucocorticoid receptor (GCR) [6].
The number of GCR varies in different organs and the
expression of GCR changes in different pathological
states [7–9]. Previous study has demonstrated that the
efficacy of glucocorticoid treatment on tumour cells
correlated with the density of GCR in lymphoid
leukaemia and lymphoma [10]. In children with
nephrotic syndrome, there have also been studies on
the relationship between the density of GCR in
mononuclear leukocytes and steroid responsiveness
[11,12], but the results were not consistent.
Nephrin, a product of the NPHS1 gene that is
mutated in patients with congenital nephrotic
syndrome of the Finnish type [13], was the first protein
demonstrated to comprise the slit diaphragm.*These two authors contributed equally to this work.
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A reduction in nephrin expression was observed in
experimental glomerular diseases [14,15] and in adult
patients with primary acquired nephrotic syndrome
[16–18], suggesting that a decrease in nephrin expres-
sion may reflect podocyte injury.
Since side-effects develop in a high proportion of
patients with prolonged glucocorticoid treatment, early
combined therapy with a second-line drug will be
beneficial in patients whose response to glucocorticoids
is expected to be unfavourable. It has been reported
that age [19] and renal function at onset, selectivity of
proteinuria and relative interstitial volume are asso-
ciated with the steroid responsiveness in adult MCD
patients [4]. However, little is known about the
relationships between the glomerular expression of
certain genes and the response to glucocorticoid
treatment in adult patients with MCD.
To determine whether steroid responsiveness is
dependent on the amount of glomerular GCR expres-
sion and the extent of podocyte injury, we compared
the expression of GCR and nephrin in microdissected
glomeruli obtained from adult MCD patients accord-
ing to the response to glucocorticoids. In addition,
the correlations between the time interval from the
start of glucocorticoid therapy to complete remission
(CR) and the glomerular expression of GCR and
nephrin were analysed.
Patients and methods
Twenty-eight adult patients with MCD confirmed by renal
biopsy for the first time in Yonsei Medical Center, Seoul,
Korea, between January 2001 and December 2005 were
included. MCD was diagnosed by a single pathologist if there
were no or who only minimal histological changes on light
microscopy, no immunofluorescence within the glomeruli,
and diffuse effacement of foot processes of podocytes
without electron-dense deposits. Any patient who had
underlying secondary causes of MCD, concomitant glomer-
ular or interstitial pathology on renal biopsy, aged less than
15, or who had been followed up for <6 months was
excluded. In addition, patients who were on glucocorticoid
treatment at the time of renal biopsy were also excluded.
Baseline demographic data (age, sex, and comorbidities, etc.)
and laboratory findings (urinalysis, haemoglobin, blood urea
nitrogen, serum creatinine, serum albumin, serum choles-
terol, 24 h urinary protein excretion, urinary protein to
creatinine ratio, selective proteinuria index, etc.) were
collected by retrospective review of the medical records of
patients.
All patients were initially treated with oral prednisolone in
a single dose of 1.0mg/kg/day and gradual tapering of the
dosage was done if CR was achieved. The time interval from
the start of glucocorticoid treatment to CR was calculated.
CR was defined as negative or trace on urine dipstick tests
and urinary protein to creatinine ratio <0.3mg/mg without
oedema. Based on the response to glucocorticoid treatment,
the patients were divided into two groups: early responders
(ER) in whom CR was achieved within 4 weeks of steroid
treatment; late responders (LR) in whom CR was achieved
after 4 weeks of steroid treatment.
A comparative analysis of the clinical and biochemical
findings was performed between the ER and LR groups.
In addition, the expression of GCR, nephrin and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in
microdissected glomeruli obtained at the time of biopsy,
assessed by real-time polymerase chain reaction (PCR) and
immunohistochemistry, were compared between the two
groups. Ten microscopic haematuric patients in whom renal
biopsy was performed and revealed no histological abnorm-
alities were included for controls (C), and glomerular GCR
mRNA and protein expression in the C group were also
compared with those in the ER and LR groups. This study
was approved by the Institutional Review Board for human
research at Yonsei University College of Medicine and
informed consent was obtained from all patients.
Microdissection and reverse transcription
Microdissection of glomeruli was performed as previously
described [20]. Glomeruli were microdissected at 48C in
vanadyl ribonucleoside complex, rinsed, aliquoted four per
tube in RNAse inhibitor, solubilized in triton buffer, and
lysed by freezing and thawing.
First-strand cDNA was made by using a Boehringer
Mannheim cDNA synthesis kit (Boehringer Mannheim
GmbH, Mannheim, Germany). Glomeruli were directly
reverse transcribed using 10 mM random hexanucleotide
primer, 1mM dNTP, 8mM MgCl2, 30mM KCl, 50mM
Tris–HCl, pH 8.5, 0.2mM dithiothreithol, 25 U RNAse
inhibitor and 40 U AMV reverse transcriptase. The mixture
was incubated at 308C for 10min and 428C for 1 h followed
by inactivation of the enzyme at 998C for 5min.
Real-time PCR
Real-time PCR was performed to determine the mRNA
expression of GCR, nephrin and GAPDH. The primers used
in this study were as follows: GCR sense 50-GCAGCGAAG
ACTTTTGGTTG-30, antisense primer 50-GTGAAACTGCT
TTGGACAGA-30; nephrin sense 50-GGTGAATTCCACCT
GCACATC-30, antisense 50-AGCTTGGGAGGAACCAGG
AT-30; and GAPDH sense 50-GATTCCACCCATGGCAAA
TT-30, antisense 50-AGATGGTGATGGGATTTCCATT-30.
Using the ABI PRISM 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA), PCR was
performed with a total volume of 20ml in each well,
containing 10 ml of SYBR Green PCR Master Mix
(Applied Biosystems), 5 ml of cDNA corresponding to one-
tenth of a glomerulus and 5 pmol sense and antisense
primers. Primer concentrations were determined by pre-
liminary experiments that analysed the optimal concentra-
tions of each primer. Each sample was run in triplicate in
separate tubes. The PCRs were performed with 35 cycles of
denaturation at 94.58C for 45 s, annealing at 608C for 45 s
and extension at 728C for 1min. Initial heating at 958C for
9min and final extension at 728C for 7min were performed
for all PCRs.
After PCR, the temperature was increased from 608C to
958C at a rate of 28C/min to construct a melting curve.
A control without cDNA was run in parallel with each assay.
The cDNA content of each specimen was determined using
a comparative CT method. The results are given as relative
expression of nephrin and GCR normalized to GAPDH and





















are expressed as CT. In pilot experiments, PCR
products run on agarose gels revealed a single band.
Immunohistochemistry
Biopsy specimens fixed in 10% neutral buffered formalin
were used for immunohistochemical staining. Four micron
sections on the slides were deparaffinized, hydrated in ethyl
alcohol and washed in tap water. Antigen retrieval was
carried out in 10mM sodium citrate buffer for 20min using a
vegetable steamer. For GCR staining, a rabbit polyclonal
anti-GCR antibody (EMD Biosciences, Inc., Darmstadt,
Germany) was diluted in 1:100 with 2% casein in BSA and
was applied for overnight incubation at room temperature.
After washing, a secondary goat anti-rabbit antibody
(Inc., Santa Cruz, Ca, USA) was added for 20min, the
slides were washed and incubated with a tertiary rabbit-PAP
complex (Santa Cruz Biotechnology, Inc.) for 20min.
Diaminobenzidine was added for 2min and the slides were
counterstained with haematoxylin. A semi-quantitative score
for measuring intensity of staining within glomeruli was
determined by examining all glomeruli (mean, 9.3 1.2
glomeruli; range, 5–18 glomeruli) in each section and by
digital image analysis (MetaMorph version 4.6r5, Universal
Imaging Corp., Downingtown, PA, USA) as previously
described [21].
Statistical analysis
All values are expressed as the mean SEM. Statistical
analysis was performed using the statistical package SPSS for
Windows Ver. 13.0 (SPSS, Inc., Chicago, IL, USA). Results
were analysed using the chi-square test or Kruskal–Wallis
non-parametric test for multiple comparisons. Significant
differences by the Kruskal–Wallis test were further con-
firmed by the Mann–Whitney U test. Correlation between
the mRNA expression of GCR and the time interval from the
start of steroid treatment to CR was determined by
Spearman correlation analysis. Statistical significance was
determined, when P-values were less than 0.05.
Results
Demographic characteristics and laboratory findings
Among 28 patients with MCD, 17 were men and 11
were women, with the mean age at the time of renal
biopsy 32.5 2.4 years. There were two patients with
hypertension and three with renal failure (serum
creatinine more than 1.5mg/dl) at presentation.
Renal failure in all the three patients was considered
a consequence of effective circulating volume deple-
tion, based on the results of urinary indices and renal
biopsy and in terms of complete recovery by
conservative treatment. The ER group consisted of
20 patients (71.4%) and the LR group of 8
patients (28.6%). The time interval from the start of
steroid treatment to CR was significantly shorter in the
ER group than that in the LR group (16.5 0.9
vs 52.8 4.9 days, P< 0.005). On the other hand,
there were no differences in age, sex ratio, patients with
hypertension or renal failure and laboratory findings
such as haemoglobin, blood urea nitrogen, serum
creatinine, serum albumin, serum cholesterol, 24 h
urinary protein excretion, selective proteinuria index
between the two groups (Table 1).
mRNA expression according to steroid responsiveness
Real-time PCR revealed that the GCR mRNA
expression normalized to GAPDH, which was
expressed as CT, was significantly lower in the
LR group (1.25 0.55) compared to the ER group
(2.17 0.61) (P< 0.01), whereas it was comparable
between the C (2.35 0.23) and ER groups
(Figure 1A). In contrast, there was no significant
difference in nephrin mRNA expression among the
three groups (Figure 1B). On the other hand, the GCR
mRNA expression correlated inversely with the time to
CR (r¼0.49, P< 0.05) (Figure 2), but not with the
amount of proteinuria at presentation (Figure 3).
Immunohistochemical staining for GCR
GCR protein expression in glomeruli, assessed by
immunohistochemical staining, showed a similar pat-
tern to the observed changes in the GCR mRNA
expression. The staining for GCR within glomeruli was
strong in cells with the location and appearance of
podocytes (Figure 4A). The mean semi-quantitative
staining scores for glomerular GCR were significantly







Time to CR (days) – 16.5 0.9 52.0 4.9#
Age at onset 33.4 3.8 32.3 2.7 32.9 5.3
Male/Female 6/4 13/7 4/4
Hypertension 1 1 (5.0%) 1 (12.5%)
Microscopic haematuria 10 1 (5.0%) 3 (37.5%)
Renal failure at
presentation
0 2 (10.0%) 1 (12.5%)
Haemoglobin (g/dl) 14.8 0.2 14.5 0.3 13.4 0.8
Albumin (g/dl) 4.3 0.5 1.8 0.4 2.1 0.6
BUN (g/dl) 13.7 2.7 21.0 2.9 19.3 5.4
Creatinine (mg/dl) 1.0 0.1 1.1 0.1 1.2 0.2
Total cholesterol
(mg/dl)
165.4 21.7 387.7 22.3 348.3 42.4
24 h urinary protein
excretion (g/24 h)
– 11.5 3.1 9.6 3.4
Selective protein
index (SPI)
– 0.16 0.04 0.19 0.04
Serum IgG (mg/dl) 897.1 107.2 415.1 48.3 665.3 280.2
Serum IgA (mg/dl) 211.1 21.4 283.0 30.8 194.7 27.7
Serum IgM (mg/dl) 128.1 16.4 145.5 17.1 157.3 18.2
C3 (mg/dl) 124.8 5.4 122.6 5.9 115.9 6.2
C4 (mg/dl) 38.6 7.1 48.0 14.5 32.4 5.6
Values are expressed as mean SEM. aER, early responders, CR
achieved within 4 weeks of steroid therapy, bLR, late responders, CR
achieved after 4 weeks of steroid therapy.
P< 0.01 vs control, #P< 0.05 vs ER.





















lower in the LR group (37.5 5.1) compared to the C
(72.9 8.1) and ER groups (74.1 10.9) (P< 0.05)
(Figure 4B).
Discussion
In this study, we show for the first time that glomerular
GCR expression is decreased in adult MCD patients
whose response to glucocorticoids is delayed. In
addition, this study shows that the time interval from
the start of steroid treatment to CR was inversely
correlated with the mRNA expression of GCR in
glomeruli.
MCD is the predominant form of nephrotic
syndrome in children, most of whom promptly respond
to glucocorticoid [1–3]. Even though the overall
response rates to steroids in adult MCD patients are
similar to those in children, the time to remission is
known to be longer in adult-onset MCD compared
with the childhood group [4–5]. It is not clear why the
response to steroids is slower in adult patients with
MCD. To clarify factors influencing the pattern of
response to steroid therapy, Nakayama et al. [4]
compared the characteristics and histological findings
between early and late responders. They demonstrated
that the incidence of microscopic haematuria and levels
of both blood urea nitrogen and serum creatinine were
significantly higher in late compared to early respon-
ders. In addition, late responders had poorer selectivity
of proteinuria and greater relative interstitial
volume than early responders. In this study, there
were no differences in the proportion of patients with
microscopic haematuria, blood urea nitrogen, serum
creatinine or selective proteinuria index between the
ER and LR groups. The reason for the divergence
of results may be due to the criteria for defining early
Fig. 1. GCR/GAPDH mRNA (A) and nephrin/GAPDH mRNA (B)
in the C, and ER and LR groups. Real-time PCR revealed that GCR
mRNA expression normalized to GAPDH, which was expressed as
CT, was significantly lower in the LR group compared with the
ER group, whereas nephrin mRNA expression normalized to
GAPDH was comparable between the two groups. The GCR/
GAPDH mRNA and nephrin/GAPDH mRNA ratios in the control
group were similar to those in the ER group. P< 0.01 vs control and
ER groups.
Fig. 2. Correlation between the GCR mRNA expression and time
interval from the start of steroid therapy to complete remission.
There was a significant inverse correlation between the mRNA
expression of GCR and the time interval from the start of steroid
treatment to complete remission.
Fig. 3. Correlation between the GCR mRNA expression and the
amount of proteinuria at presentation. There was no significant
correlation between the mRNA expression of GCR and the amount
of proteinuria.





















and late responders (the time to remission: 4 vs
8 weeks). Compared to the study by Nakayama et al.
[4], the response rates to steroids at the corresponding
time course were higher and only three patients
achieved CR after 8 weeks of steroid treatment in
this study. Therefore, we could not classify the subjects
according to the same method as Nakayama et al. [4].
Huang et al. [22] also divided the patients into early
and late responders according to the response to
glucocorticoids on the basis of 4 weeks as in this study,
and compared the frequency of relapse, but did not
investigate the differences in clinical or laboratory
findings between the two groups.
Even though abnormal immune function, especially
disturbances in T-cell function, has been supposed to
be implicated in the pathogenesis of MCD [23], the
detail action mechanisms of glucocorticoid in this
disease have not been clearly explored. Glucocorticoids
act by binding to intracellular GCR, which results in
the formation of glucocorticoid–GCR complex, and
then this complex is translocated to the nucleus and
binds to the DNA and acts as a transcription factor [6].
The number of GCR varies in different pathological
states and individual differences also exist in the
expression of GCR. Previous studies have demon-
strated that the concentrations of GCR in peripheral
mononuclear leukocytes were closely related to the
steroid responsiveness in various autoimmune diseases
such as rheumatoid arthritis [7], lupus nephritis [8] and
asthma [9]. Based on the possibility of the involvement
of cellular immune disturbance in the pathogenesis of
MCD, Bagdasorova et al. [11] examined the associa-
tion of GCR number in monocytes and steroid
responsiveness in patients with nephrotic syndrome
and reported a higher expression of GCR in steroid-
sensitive than in steroid-resistant patients. In contrast,
Haack et al. [12] did not find any difference in density
and binding affinity of GCR in mononuclear leuko-
cytes between steroid-sensitive and steroid-resistant
nephrotic syndrome children and raised a probability
that steroid sensitivity may depend on other factors
such as the amount of GCR in renal tissue.
In fact, there have been some reports that changes in
the expression of GCR in target tissue may play an
important role in steroid resistance in various diseases.
Inhibition of GCR expression by oestradiol induced
steroid resistance in human breast cancer cells [24] and
transformed mouse lung cells stably transfected with
GCR gene acquired glucocorticoid responsiveness [25].
Moreover, the efficacy of glucocorticoid treatment on
tumour cells correlated with the density of GCR in
lymphoid leukaemia and lymphoma [10]. In kidney,
GCR is known to be widely distributed with intense
expression in distal convoluted tubules and collecting
ducts, faint expression in proximal tubules, and
moderate expression in glomerular cells, including
mesangial cells, endothelial cells and podocytes [26]
and potentially mediates the pharmacological effects of
Fig. 4. (A) A representative immunohistochemical staining for GCR protein in the C, and ER and LR groups. The staining for GCR within
glomeruli was strong in cells with the location and appearance of podocytes (arrow heads). (400) (B) The mean semi-quantitative staining
scores for glomerular GCR were significantly lower in the LR group compared with the C and ER groups. P< 0.05 vs C and ER groups.





















synthetic glucocorticoid. Recent study also demon-
strated that dexamethasone not only up-regulated
nephrin and tubulin-a expression but also suppressed
cytokine production in human podocytes, suggesting a
potent effect of glucocorticoids directly on podocytes
[27]. However, there has been no study on the
relationship between the expression of glomerular
GCR and the sensitivity to steroids in patients with
nephrotic syndrome so far. In this study, we demon-
strated for the first time that glomerular GCR
expression was lower in late compared with early
responders and was negatively correlated with the time
interval to remission.
Podocyte injury is a key component of the process in
various glomerular diseases characterized by protei-
nuria. The underlying pathological change responsible
for glomerular proteinuria is the loss of size-selective
and/or charge-selective properties of the glomerular
filtration barrier [28], and nephrin is known to serve as
a basic scaffold for the slit diaphragm and play a
central role in the glomerular filtration barrier [29,30].
Recent studies have demonstrated that nephrin expres-
sion was reduced in experimental and human protei-
nuric diseases [16–18], suggesting that a decrease
in nephrin expression may reflect podocyte injury.
For this reason, we speculated that severer injury to
podocytes expressed as more decreased expression of
nephrin may require longer treatment duration to
induce remission. The mRNA expression of nephrin,
however, was not different between the ER and LR
groups. Moreover, its expression was comparable
between C and patients with MCD. Further study
will be needed to clarify whether decreased nephrin
expression is a real sensitive marker of podocyte injury
and whether podocyte injury is involved in the
pathogenesis of MCD.
In conclusion, glomerular GCR expression was
significantly lower in late than in early responders
and there was a significant inverse correlation between
the expression of GCR and the time interval from the
start of steroid treatment to CR. These findings suggest
that the levels of GCR expression may be useful
predictors of steroid responsiveness in adult-onset
MCD patients.
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